David A. Siegel Compass Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 86,400 shares of CMPX stock, worth $126,144. This represents 0.0% of its overall portfolio holdings.

Number of Shares

86,400

Previous 113,800 24.08%

Holding current value

$126,144

Previous $113,000 39.82%

% of portfolio

0.0%

Previous 0.0%

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.8 - $1.88 $21,920 - $51,512	-27,400 Reduced 24.08%	86,400 $158,000
Q2 2024 Aug 14, 2024	BUY	$1.0 - $1.85 $54,500 - $100,825	54,500 Added 91.91%	113,800 $113,000
Q1 2024 May 15, 2024	SELL	$1.2 - $2.29 $13,800 - $26,335	-11,500 Reduced 16.24%	59,300 $117,000
Q4 2023 Feb 14, 2024	BUY	$1.4 - $1.98 $45,080 - $63,756	32,200 Added 83.42%	70,800 $110,000
Q3 2023 Nov 14, 2023	BUY	$1.87 - $3.25 $72,182 - $125,450	38,600 New	38,600 $76,000

Others Institutions Holding CMPX

# of Institutions

Shares Held

91.9M

Call Options Held

Put Options Held

View Full List

About Compass Therapeutics, Inc.

Ticker CMPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 101,285,000
Market Cap $148M
Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...

More about CMPX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account